![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Effects of Combining Two Gilead Direct Acting Antivirals GS-9256+GS-9190, Ribavirin, and Pegylated Interferon on the Detection of Drug Resistance Mutations Early in Treatment of HCV
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
CM Hebner, R Martin, S Knox, MD Miller, H Mo, ES Svarovskaia
Gilead Sciences, Foster City, CA United States
![AASLD1.gif](../images/111411/111411-10/AASLD1.gif)
![AASLD2.gif](../images/111411/111411-10/AASLD2.gif)
![AASLD3.gif](../images/111411/111411-10/AASLD3.gif)
![AASLD4.gif](../images/111411/111411-10/AASLD4.gif)
![AASLD5.gif](../images/111411/111411-10/AASLD5.gif)
![AASLD6.gif](../images/111411/111411-10/AASLD6.gif)
![AASLD7.gif](../images/111411/111411-10/AASLD7.gif)
![AASLD8.gif](../images/111411/111411-10/AASLD8.gif)
![AASLD9.gif](../images/111411/111411-10/AASLD9.gif)
![AASLD10.gif](../images/111411/111411-10/AASLD10.gif)
![AASLD11.gif](../images/111411/111411-10/AASLD11.gif)
![AASLD12.gif](../images/111411/111411-10/AASLD12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|